Ionotropic glutamate-receptor antagonists inhibit the aversive effects of nitric oxide donor injected into the dorsolateral periaqueductal gray of rats.

Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7608025 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0033-3158 (Print) Linking ISSN: 00333158 NLM ISO Abbreviation: Psychopharmacology (Berl) Subsets: MEDLINE

Original Publication: Berlin, New York, Springer-Verlag.

2-Amino-5-phosphonovalerate/*analogs & derivatives ; Excitatory Amino Acid Antagonists/*pharmacology ; Motor Activity/*drug effects ; Nitric Oxide Donors/*pharmacology ; Periaqueductal Gray/*drug effects; 2-Amino-5-phosphonovalerate/pharmacology ; Animals ; Male ; Molsidomine/analogs & derivatives ; Molsidomine/pharmacology ; Nitric Oxide/metabolism ; Periaqueductal Gray/metabolism ; Rats ; Rats, Wistar ; Receptors, AMPA/agonists ; Receptors, AMPA/antagonists & inhibitors ; Receptors, Kainic Acid/agonists ; Receptors, Kainic Acid/antagonists & inhibitors ; Receptors, N-Methyl-D-Aspartate/agonists ; Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors ; Time Factors

Rationale: Nitric oxide (NO) is a gas neurotransmitter that may facilitate glutamate release in the central nervous system. NO donors or glutamate agonists injected into the dorsolateral periaqueductal grey (dlPAG) induce flight behaviour.
Objectives: To test the hypothesis that the defensive reactions induced by an NO donor in the dlPAG would be attenuated by pretreatment with AMPA/kainate or NMDA glutamate receptor antagonists.
Methods: Male Wistar rats with cannulae aimed at the dlPAG received vehicle, AP7 (a NMDA receptor antagonist, 2 nmol) or NBQX (an AMPA/kainite receptor antagonist, 100 nmol) injection 10 min before the administration of SIN-1 (an NO donor, 300 nmol). Immediately after the last injection, their behavior was observed in an open arena during 10 min.
Results: SIN-1 induced flight reactions characterized by running and jumps. Pretreatment with AP7 or NBQX completely prevented the effects of SIN-1.
Conclusion: The results suggest that the aversive reactions induced by an NO donor in the dlPAG depend on ionotropic glutamate receptor activation.

Science. 1994 Feb 18;263(5149):973-7. (PMID: 7508638)
Prog Neurobiol. 1998 Apr;54(5):581-618. (PMID: 9550192)
Braz J Med Biol Res. 1999 Dec;32(12):1529-32. (PMID: 10585635)
Brain Res. 1997 Aug 15;765(2):208-17. (PMID: 9313893)
Nature. 1988 Nov 24;336(6197):385-8. (PMID: 2904125)
Behav Brain Res. 1993 Dec 20;58(1-2):27-47. (PMID: 8136048)
Brain Res Bull. 2000 Apr;51(6):457-64. (PMID: 10758334)
Neuroreport. 1999 Feb 5;10(2):413-8. (PMID: 10203345)
Neurosci Biobehav Rev. 2001 Dec;25(7-8):647-59. (PMID: 11801290)
Neurosci Lett. 1990 Oct 2;118(1):112-5. (PMID: 2175406)
Behav Brain Res. 2000 Jun 15;111(1-2):175-85. (PMID: 10840143)
J Neurochem. 1994 Feb;62(2):807-10. (PMID: 7905029)
Anesthesiol Clin North America. 2002 Jun;20(2):265-92. (PMID: 12165994)
Psychopharmacology (Berl). 2002 Feb;160(1):30-8. (PMID: 11862371)
Trends Neurosci. 1997 Jul;20(7):298-303. (PMID: 9223222)
J Comp Neurol. 2000 Jul 10;422(4):556-78. (PMID: 10861526)
Neuroreport. 1998 Mar 9;9(4):571-6. (PMID: 9559918)
Eur J Pharmacol. 2000 Oct 27;407(1-2):83-9. (PMID: 11050294)
Neurosci Lett. 1991 Sep 2;130(1):107-11. (PMID: 1660968)
Neurosci Biobehav Rev. 2001 Dec;25(7-8):679-85. (PMID: 11801293)
Braz J Med Biol Res. 1985;18(1):61-7. (PMID: 4063549)
Neuroreport. 1994 Oct 3;5(15):1929-32. (PMID: 7531004)
Brain Res Bull. 2000 Sep 1;53(1):95-104. (PMID: 11033213)
Brain Res. 2000 Oct 13;880(1-2):1-10. (PMID: 11032984)
Brain Res. 1998 Sep 14;805(1-2):69-87. (PMID: 9733923)
Psychopharmacology (Berl). 2001 May;155(3):260-8. (PMID: 11432688)
Brain Res. 1993 May 7;610(2):317-24. (PMID: 7686435)
Neurosci Lett. 1997 Jan 17;221(2-3):197-201. (PMID: 9121698)
Proc Natl Acad Sci U S A. 1989 Jul;86(13):5159-62. (PMID: 2567995)
J Psychopharmacol. 1991 Jan;5(4):305-15. (PMID: 22282829)
Exp Brain Res. 1996 Mar;108(3):382-8. (PMID: 8801118)
Neuroscience. 1997 Oct;80(3):821-7. (PMID: 9276497)
Psychiatry Res. 1995 Jul 28;57(2):181-91. (PMID: 7480384)
Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11651-2. (PMID: 1334544)
Proc Natl Acad Sci U S A. 1989 Nov;86(22):9030-3. (PMID: 2573074)
J Comp Neurol. 1997 Jan 27;377(4):509-19. (PMID: 9007189)
Eur J Pharmacol. 1989 Oct 17;172(4-5):413-6. (PMID: 2555211)
Psychopharmacology (Berl). 1991;103(1):91-4. (PMID: 1672463)
Prog Neurobiol. 2001 May;64(1):97-108. (PMID: 11250064)
Braz J Med Biol Res. 1994 Apr;27(4):811-29. (PMID: 7916235)
Trends Pharmacol Sci. 1991 Apr;12(4):125-8. (PMID: 1712138)
Neuroscience. 1998 Oct;86(3):695-9. (PMID: 9692709)
Naunyn Schmiedebergs Arch Pharmacol. 1996 Dec;354(6):731-5. (PMID: 8971733)
Braz J Med Biol Res. 1981 Oct;14(4-5):239-65. (PMID: 6124290)
Brain Res. 1988 Jan 26;439(1-2):95-106. (PMID: 3359200)
Psychopharmacology (Berl). 1997 Jul;132(1):14-8. (PMID: 9272754)
Trends Neurosci. 1991 Feb;14(2):60-7. (PMID: 1708538)
Neurosci Lett. 2000 Aug 4;289(2):123-6. (PMID: 10904135)

0 (Excitatory Amino Acid Antagonists)
0 (Nitric Oxide Donors)
0 (Receptors, AMPA)
0 (Receptors, Kainic Acid)
0 (Receptors, N-Methyl-D-Aspartate)
31C4KY9ESH (Nitric Oxide)
5O5U71P6VQ (linsidomine)
76726-92-6 (2-Amino-5-phosphonovalerate)
D46583G77X (Molsidomine)
P34K80CUSM (2-amino-7-phosphonoheptanoic acid)

Date Created: 20030905 Date Completed: 20040727 Latest Revision: 20181113

20231215

10.1007/s00213-003-1569-9

12955288